Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pfizer (PFE) Tops Q4 EPS by 15c, Beats on Revenue; Offers FY25 Guidance
February 4, 2025 6:46 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.63, $0.15 better than the analyst estimate of $0.48. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.28 billion.
GUIDANCE:
Pfizer sees FY2025 EPS of $2.80-$3.00, versus the consensus of $2.93. Pfizer... More
